Alzheimer’s disease risk gene is involved in synaptic transmission

A study published today in the journal Cell Reports sheds new light on how the CD2AP gene may enhance Alzheimer's disease susceptibility. Integrating experiments in fruit flies, mice and human brains, a multi-institutional team led by researchers at Baylor College of Medicine found that the CD2AP gene is involved in synaptic transmission, the process by which neurons communicate. Digging deeper, the researchers discovered that CD2AP affects neuronal communication by regulating the levels of key regulatory proteins present at neuron terminals (synapses).

Dr. Joshua Shulman, associate professor of neurology at Baylor and corresponding author of the work, explains that they first worked with the laboratory fruit fly to test the effect of deleting the gene in the brain. The team deleted the fly equivalent of the human CD2AP gene, called cindr, and observed evidence of defective synapse structure and function. They also found that certain proteins accumulated more in the synapses of mutant flies. Among the accumulated proteins were several that regulate neural communication.

To connect these findings with Alzheimer's disease, Shulman and his colleagues also studied a mouse in which the CD2AP gene was deleted and discovered brain changes similar to those they had found in flies. Finally, in order to establish relevance for humans, they examined a collection of more than 800 brain autopsies. Shulman and colleagues found that low CD2AP levels significantly correlated with abnormal turnover of synaptic proteins, and this relationship was enhanced in the setting of Alzheimer's disease.

Source:
Journal reference:

Ojelade, S.A. et al. (2019) cindr, the Drosophila Homolog of the CD2AP Alzheimer’s Disease Risk Gene, Is Required for Synaptic Transmission and Proteostasis. Cell Reports. doi.org/10.1016/j.celrep.2019.07.041.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First U.S. trial uses non-viral CRISPR to correct sickle cell mutation